OGECHI AMACHUKWU: Open Payments
NPI 1679013429 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,205 in 65 payments from 18 companies in 2025. Trend: 2023 $105 · 2024 $1,973 · 2025 $7,205
Consulting: $5,625Food & beverage: $1,580
| Company | Payments | Amount |
|---|---|---|
| Intrinsic Therapeutics | 14 | $5,976 |
| ABBVIE INC. | 21 | $392 |
| Merz Pharmaceuticals, LLC | 8 | $191 |
| Globus Medical, Inc. | 1 | $150 |
| SK Life Science, Inc. | 3 | $81 |
| UCB, Inc. | 3 | $68 |
| Averitas Pharma Inc. | 2 | $43 |
| Eisai Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
Products named: BARRICAID ACD (ANNULAR CLOSURE DEVICE), BOTOX, Xeomin, EXCELSIUS GPS, QULIPTA, Rystiggo, QUTENZA, Leqembi.
Industry payments across TX — which companies pay providers there.
